{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T16:23:27Z","timestamp":1648571007951},"reference-count":112,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"DOI":"10.1007\/s00105-019-4385-9","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T11:05:01Z","timestamp":1552907101000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aktuelle Therapie des Pemphigus"],"prefix":"10.1007","author":[{"given":"N.","family":"van Beek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"4385_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","volume":"14","author":"AR Ahmed","year":"2015","unstructured":"Ahmed AR, Shetty S (2015) A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev 14:323\u2013331","journal-title":"Autoimmun Rev"},{"key":"4385_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","volume":"60","author":"M Amagai","year":"2009","unstructured":"Amagai M, Ikeda S, Shimizu H et al (2009) A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J\u00a0Am Acad Dermatol 60:595\u2013603","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/jamadermatol.2017.2808","volume":"153","author":"KT Amber","year":"2017","unstructured":"Amber KT, Lamberts A, Solimani F et\u00a0al (2017) Determining the incidence of pneumocystis pneumonia in patients with autoimmune blistering diseases not receiving routine prophylaxis. Jama Dermatol 153:1137\u20131141","journal-title":"Jama Dermatol"},{"key":"4385_CR4","first-page":"Abs023","volume":"125","author":"G Anhalt","year":"2005","unstructured":"Anhalt G, Strober B, Connolly M, Korman N, Greenstein D, Fantasia J, Kalish R (2005) An open-label phase I clinical study to assess the safety of PI-0824 in patients with pemphigus vulgaris. J\u00a0Invest Dermatol 125:Abs23","journal-title":"J Invest Dermatol"},{"key":"4385_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1087-0024.2004.00832.x","volume":"9","author":"GJ Anhalt","year":"2004","unstructured":"Anhalt GJ (2004) Paraneoplastic pemphigus. J\u00a0Investig Dermatol Symp Proc 9:29\u201333","journal-title":"J Investig Dermatol Symp Proc"},{"key":"4385_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/sj.jid.5700016","volume":"126","author":"M Aoki-Ota","year":"2006","unstructured":"Aoki-Ota M, Kinoshita M, Ota T et al (2006) Tolerance induction by the blockade of CD40\/CD154 interaction in pemphigus vulgaris mouse model. J\u00a0Invest Dermatol 126:105\u2013113","journal-title":"J Invest Dermatol"},{"key":"4385_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1346-8138.2009.00796.x","volume":"37","author":"Y Aoyama","year":"2010","unstructured":"Aoyama Y (2010) What\u2019s new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus. J\u00a0Dermatol 37:239\u2013245","journal-title":"J Dermatol"},{"key":"4385_CR8","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1468-3083.2009.03226.x","volume":"23","author":"EB Baskan","year":"2009","unstructured":"Baskan EB, Yilmaz M, Tunali S et al (2009) Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris. J\u00a0Eur Acad Dermatol Venereol 23:1432\u20131434","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4385_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1159\/000448028","volume":"232","author":"S Baum","year":"2016","unstructured":"Baum S, Debby A, Gilboa S et al (2016) Efficacy of Dapsone in the treatment of pemphigus vulgaris: a single-center case study. Dermatology 232:578\u2013585","journal-title":"Dermatology"},{"key":"4385_CR10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1684\/ejd.2011.1611","volume":"22","author":"S Baum","year":"2012","unstructured":"Baum S, Greenberger S, Samuelov L et\u00a0al (2012) Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol 22:83\u201387","journal-title":"Eur J Dermatol"},{"key":"4385_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1365-2133.2011.10732.x","volume":"166","author":"M Behzad","year":"2012","unstructured":"Behzad M, Mobs C, Kneisel A et al (2012) Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 166:844\u2013852","journal-title":"Br J Dermatol"},{"key":"4385_CR12","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/jid.2010.91","volume":"130","author":"S Beissert","year":"2010","unstructured":"Beissert S, Mimouni D, Kanwar AJ et al (2010) Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a\u00a0multicenter, randomized, placebo-controlled trial. J\u00a0Invest Dermatol 130:2041\u20132048","journal-title":"J Invest Dermatol"},{"key":"4385_CR13","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","volume":"142","author":"S Beissert","year":"2006","unstructured":"Beissert S, Werfel T, Frieling U et\u00a0al (2006) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 142:1447\u20131454","journal-title":"Arch Dermatol"},{"key":"4385_CR14","doi-asserted-by":"publisher","first-page":"12855","DOI":"10.1073\/pnas.0602973103","volume":"103","author":"P Berkowitz","year":"2006","unstructured":"Berkowitz P, Hu P, Warren S et\u00a0al (2006) p38MAPK inhibition prevents disease in pemphigus vulgaris mice. Proc Natl Acad Sci U S\u00a0A 103:12855\u201312860","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4385_CR15","first-page":"434","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram F, Brocker EB, Zillikens D et\u00a0al (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J\u00a0Dtsch Dermatol Ges 7:434\u2013440","journal-title":"J Dtsch Dermatol Ges"},{"key":"4385_CR16","unstructured":"Bvba A (2017) An open-label, non-controlled, phase II study to evaluate the safety, pharmacodynamics, pharmacokinetics, efficacy and conditions of use of ARGX-113 in patients with mild to moderate pemphigus (vulgaris and foliaceus). clinicaltrials.gov: NCT03334058"},{"key":"4385_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","volume":"132","author":"JC Bystryn","year":"1996","unstructured":"Bystryn JC, Steinman NM (1996) The adjuvant therapy of pemphigus. An update. Arch Dermatol 132:203\u2013212","journal-title":"Arch Dermatol"},{"key":"4385_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.01.062","volume":"76","author":"A Caplan","year":"2017","unstructured":"Caplan A, Fett N, Rosenbach M et al (2017) Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J\u00a0Am Acad Dermatol 76:1\u20139","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","volume":"57","author":"C Chams-Davatchi","year":"2007","unstructured":"Chams-Davatchi C, Esmaili N, Daneshpazhooh M et al (2007) Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J\u00a0Am Acad Dermatol 57:622\u2013628","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR20","first-page":"1285","volume":"27","author":"C Chams-Davatchi","year":"2013","unstructured":"Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M et al (2013) Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J\u00a0Eur Acad Dermatol Venereol 27:1285\u20131292","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4385_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","volume":"67","author":"G Cianchini","year":"2012","unstructured":"Cianchini G, Lupi F, Masini C et al (2012) Therapy with rituximab for autoimmune pemphigus: results from a\u00a0single-center observational study on 42 cases with long-term follow-up. J\u00a0Am Acad Dermatol 67:617\u2013622","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR22","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/j.1365-4632.2006.02901.x","volume":"45","author":"SN Cohen","year":"2006","unstructured":"Cohen SN, Lim RP, Paul CJ et\u00a0al (2006) Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. Int J Dermatol 45:1379","journal-title":"Int J Dermatol"},{"key":"4385_CR23","doi-asserted-by":"publisher","first-page":"175ra130","DOI":"10.1126\/scitranslmed.3005166","volume":"5","author":"N Colliou","year":"2013","unstructured":"Colliou N, Picard D, Caillot F et al (2013) Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med 5:175ra130","journal-title":"Sci Transl Med"},{"key":"4385_CR24","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jaad.2010.06.033","volume":"65","author":"EE Craythorne","year":"2011","unstructured":"Craythorne EE, Mufti G, Duvivier AW (2011) Rituximab used as a\u00a0first-line single agent in the treatment of pemphigus vulgaris. J\u00a0Am Acad Dermatol 65:1064\u20131065","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1529-8019.2012.01450.x","volume":"25","author":"C Simone De","year":"2012","unstructured":"De Simone C, Caldarola G, Perino F et al (2012) Enteric-coated mycophenolate sodium as a\u00a0steroid-sparing agent in pemphigus treatment: a\u00a0retrospective study. Dermatol Ther 25:219\u2013222","journal-title":"Dermatol Ther"},{"key":"4385_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/08916930600972008","volume":"39","author":"SE Dick","year":"2006","unstructured":"Dick SE, Werth VP (2006) Pemphigus: a\u00a0treatment update. Autoimmunity 39:591\u2013599","journal-title":"Autoimmunity"},{"key":"4385_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A et\u00a0al (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353:179\u2013184","journal-title":"Science"},{"key":"4385_CR28","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","volume":"150","author":"CT Ellebrecht","year":"2014","unstructured":"Ellebrecht CT, Choi EJ, Allman DM et al (2014) Subcutaneous veltuzumab, a\u00a0humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. Jama Dermatol 150:1331\u20131335","journal-title":"Jama Dermatol"},{"key":"4385_CR29","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.4049\/jimmunol.1401081","volume":"193","author":"R Eming","year":"2014","unstructured":"Eming R, Hennerici T, Backlund J et al (2014) Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells. J\u00a0Immunol 193:4391\u20134399","journal-title":"J Immunol"},{"key":"4385_CR30","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1038\/jid.2008.172","volume":"128","author":"R Eming","year":"2008","unstructured":"Eming R, Nagel A, Wolff-Franke S et al (2008) Rituximab exerts a\u00a0dual effect in pemphigus vulgaris. J\u00a0Invest Dermatol 128:2850\u20132858","journal-title":"J Invest Dermatol"},{"key":"4385_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000090659","volume":"212","author":"R Eming","year":"2006","unstructured":"Eming R, Rech J, Barth S et al (2006) Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 212:177\u2013187","journal-title":"Dermatology"},{"key":"4385_CR32","first-page":"833","volume":"13","author":"R Eming","year":"2015","unstructured":"Eming R, Sticherling M, Hofmann SC et\u00a0al (2015) S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid. J\u00a0Dtsch Dermatol Ges 13:833\u2013844","journal-title":"J Dtsch Dermatol Ges"},{"key":"4385_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","volume":"157","author":"L Fardet","year":"2007","unstructured":"Fardet L, Flahault A, Kettaneh A et al (2007) Corticosteroid-induced clinical adverse events: frequency, risk factors and patient\u2019s opinion. Br J Dermatol 157:142\u2013148","journal-title":"Br J Dermatol"},{"key":"4385_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1586\/eci.11.22","volume":"7","author":"RJ Feldman","year":"2011","unstructured":"Feldman RJ, Ahmed AR (2011) Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol 7:529\u2013541","journal-title":"Expert Rev Clin Immunol"},{"key":"4385_CR35","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL et\u00a0al (2017) Cytokine Release Syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 45:e124\u2013e131","journal-title":"Crit Care Med"},{"key":"4385_CR36","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (hoboken) 62:1515\u20131526","journal-title":"Arthritis Care Res (hoboken)"},{"key":"4385_CR37","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","volume":"161","author":"HM Gurcan","year":"2009","unstructured":"Gurcan HM, Ahmed AR (2009) Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 161:723\u2013731","journal-title":"Br J Dermatol"},{"key":"4385_CR38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","volume":"10","author":"HM Gurcan","year":"2009","unstructured":"Gurcan HM, Ahmed AR (2009) Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 10:383\u2013396","journal-title":"Am J Clin Dermatol"},{"key":"4385_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1046\/j.1468-3083.2002.00384.x","volume":"16","author":"K Hahn-Ristic","year":"2002","unstructured":"Hahn-Ristic K, Rzany B, Amagai M et al (2002) Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J\u00a0Eur Acad Dermatol Venereol 16:68\u201371","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4385_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","volume":"11","author":"CM Hammers","year":"2016","unstructured":"Hammers CM, Stanley JR (2016) Mechanisms of disease: Pemphigus and Bullous Pemphigoid. Annu Rev Pathol 11:175\u2013197","journal-title":"Annu Rev Pathol"},{"key":"4385_CR41","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.15930","volume":"177","author":"KE Harman","year":"2017","unstructured":"Harman KE, Brown D, Exton LS et\u00a0al (2017) British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 177:1170\u20131201","journal-title":"Br J Dermatol"},{"key":"4385_CR42","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1046\/j.1365-2133.2003.05209_10.x","volume":"148","author":"G Herrmann","year":"2003","unstructured":"Herrmann G, Hunzelmann N, Engert A (2003) Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 148:602\u2013603","journal-title":"Br J Dermatol"},{"key":"4385_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jdv.12772","volume":"29","author":"M Hertl","year":"2015","unstructured":"Hertl M, Jedlickova H, Karpati S et\u00a0al (2015) Pemphigus. S2 Guideline for diagnosis and treatment\u2014guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J\u00a0Eur Acad Dermatol Venereol 29:405\u2013414","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4385_CR44","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","volume":"6","author":"M Hertl","year":"2008","unstructured":"Hertl M, Zillikens D, Borradori L et al (2008) Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J\u00a0Dtsch Dermatol Ges 6:366\u2013373","journal-title":"J Dtsch Dermatol Ges"},{"key":"4385_CR45","doi-asserted-by":"publisher","first-page":"8589","DOI":"10.1074\/jbc.M808813200","volume":"284","author":"WM Heupel","year":"2009","unstructured":"Heupel WM, Muller T, Efthymiadis A et al (2009) Peptides targeting the Desmoglein 3 adhesive interface prevent autoantibody-induced acantholysis in pemphigus. J\u00a0Biol Chem 284:8589\u20138595","journal-title":"J Biol Chem"},{"key":"4385_CR46","first-page":"1935","volume":"9","author":"M Hofrichter","year":"2018","unstructured":"Hofrichter M, Dworschak J, Emtenani S et al (2018) Immunoadsorption of Desmoglein-3-specific IgG abolishes the blister-inducing capacity of pemphigus vulgaris IgG in neonatal mice. FrontImmunol 9:1935","journal-title":"FrontImmunol"},{"key":"4385_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","volume":"166","author":"B Horvath","year":"2012","unstructured":"Horvath B, Huizinga J, Pas HH et al (2012) Low-dose rituximab is effective in pemphigus. Br J Dermatol 166:405\u2013412","journal-title":"Br J Dermatol"},{"key":"4385_CR48","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jaad.2015.11.008","volume":"74","author":"A Huang","year":"2016","unstructured":"Huang A, Madan RK, Levitt J (2016) Future therapies for pemphigus vulgaris: Rituximab and beyond. J\u00a0Am Acad Dermatol 74:746\u2013753","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00105-018-4315-2","volume":"70","author":"F Hubner","year":"2018","unstructured":"Hubner F, Kasperkiewicz M, Zillikens D et\u00a0al (2018) Immunoadsorption in dermatology. Hautarzt 70:51\u201363","journal-title":"Hautarzt"},{"key":"4385_CR50","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","volume":"136","author":"F Hubner","year":"2016","unstructured":"Hubner F, Recke A, Zillikens D et\u00a0al (2016) Prevalence and age distribution of Pemphigus and Pemphigoid diseases in Germany. J\u00a0Invest Dermatol 136:2495\u20132498","journal-title":"J Invest Dermatol"},{"key":"4385_CR51","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","volume":"68","author":"D Huscher","year":"2009","unstructured":"Huscher D, Thiele K, Gromnica-Ihle E et al (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119\u20131124","journal-title":"Ann Rheum Dis"},{"key":"4385_CR52","unstructured":"Inc. PB (2016) An open-label, phase 2, pilot study investigating the safety, clinical activity, pharmacokinetics, and pharmacodynamics of oral treatment with the BTK inhibitor PRN1008 in patients with newly diagnosed or relapsing pemphigus vulgaris. clinicaltrials.gov"},{"key":"4385_CR53","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1468-3083.2011.04170.x","volume":"26","author":"D Ioannides","year":"2012","unstructured":"Ioannides D, Apalla Z, Lazaridou E et al (2012) Evaluation of mycophenolate mofetil as a\u00a0steroid-sparing agent in pemphigus: a\u00a0randomized, prospective study. J\u00a0Eur Acad Dermatol Venereol 26:855\u2013860","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4385_CR54","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C et al (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a\u00a0prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389:2031\u20132040","journal-title":"Lancet"},{"key":"4385_CR55","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","volume":"357","author":"P Joly","year":"2007","unstructured":"Joly P, Mouquet H, Roujeau JC et\u00a0al (2007) A single cycle of rituximab for the treatment of severe pemphigus. N\u00a0Engl J Med 357:545\u2013552","journal-title":"N Engl J Med"},{"key":"4385_CR56","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4103\/0378-6323.102354","volume":"78","author":"AJ Kanwar","year":"2012","unstructured":"Kanwar AJ, Vinay K (2012) Rituximab in pemphigus. Indian J Dermatol Venereol Leprol 78:671\u2013676","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"4385_CR57","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/bjd.12972","volume":"170","author":"AJ Kanwar","year":"2014","unstructured":"Kanwar AJ, Vinay K, Sawatkar GU et al (2014) Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a\u00a0randomized, comparative, observer-blinded study. Br J Dermatol 170:1341\u20131349","journal-title":"Br J Dermatol"},{"key":"4385_CR58","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","volume":"3","author":"M Kasperkiewicz","year":"2017","unstructured":"Kasperkiewicz M, Ellebrecht CT, Takahashi H et\u00a0al (2017) Pemphigus. Nat Rev Dis Primers 3:17026","journal-title":"Nat Rev Dis Primers"},{"key":"4385_CR59","first-page":"727","volume":"10","author":"M Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M, Eming R, Behzad M et\u00a0al (2011) Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J\u00a0Dtsch Dermatol Ges 10:727\u2013732","journal-title":"J Dtsch Dermatol Ges"},{"key":"4385_CR60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clindermatol.2011.03.014","volume":"30","author":"M Kasperkiewicz","year":"2012","unstructured":"Kasperkiewicz M, Schmidt E, Zillikens D (2012) Current therapy of the pemphigus group. Clin Dermatol 30:84\u201394","journal-title":"Clin Dermatol"},{"key":"4385_CR61","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","volume":"65","author":"M Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M, Shimanovich I, Ludwig RJ et al (2011) Rituximab for treatment-refractory pemphigus and pemphigoid: a\u00a0case series of 17 patients. J\u00a0Am Acad Dermatol 65:552\u2013558","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR62","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","volume":"166","author":"M Kasperkiewicz","year":"2012","unstructured":"Kasperkiewicz M, Shimanovich I, Meier M et\u00a0al (2012) Treatment of severe pemphigus with a\u00a0combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a\u00a0pilot study of 23 patients. Br J Dermatol 166:154\u2013160","journal-title":"Br J Dermatol"},{"key":"4385_CR63","first-page":"523","volume-title":"Blistering diseases: clinical features, pathogenesis, treatment","author":"JDB Kim","year":"2015","unstructured":"Kim JDB, Werth VP, Joly P, Murrell DF (2015) The treatment of pemphigus vulgaris and pemphigus foliaceus. In: Murrell D (Hrsg) Blistering diseases: clinical features, pathogenesis, treatment. Springer, Berlin Heidelberg, S\u00a0523\u2013531"},{"key":"4385_CR64","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S142471","volume":"14","author":"K Kridin","year":"2018","unstructured":"Kridin K (2018) Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag 14:757\u2013778","journal-title":"Ther Clin Risk Manag"},{"key":"4385_CR65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/exd.12355","volume":"23","author":"J Langenhan","year":"2014","unstructured":"Langenhan J, Dworschak J, Saschenbrecker S et\u00a0al (2014) Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. Exp Dermatol 23:253\u2013259","journal-title":"Exp Dermatol"},{"key":"4385_CR66","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/archdermatol.2012.1830","volume":"148","author":"S Leger","year":"2012","unstructured":"Leger S, Picard D, Ingen-Housz-Oro S et al (2012) Prognostic factors of paraneoplastic pemphigus. Arch Dermatol 148:1165\u20131172","journal-title":"Arch Dermatol"},{"key":"4385_CR67","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","volume":"130","author":"L Lunardon","year":"2012","unstructured":"Lunardon L, Payne AS (2012) Inhibitory human antichimeric antibodies to rituximab in a\u00a0patient with pemphigus. J\u00a0Allergy Clin Immunol 130:800\u2013803","journal-title":"J Allergy Clin Immunol"},{"key":"4385_CR68","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","volume":"64","author":"LK Martin","year":"2011","unstructured":"Martin LK, Werth VP, Villaneuva EV et\u00a0al (2011) A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J\u00a0Am Acad Dermatol 64:903\u2013908","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR69","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/j.1365-2133.2011.10575.x","volume":"165","author":"SJ Meggitt","year":"2011","unstructured":"Meggitt SJ, Anstey AV, Mohd Mustapa MF et\u00a0al (2011) British Association of Dermatologists\u2019 guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 165:711\u2013734","journal-title":"Br J Dermatol"},{"key":"4385_CR70","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clindermatol.2011.03.013","volume":"30","author":"M Meurer","year":"2012","unstructured":"Meurer M (2012) Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol 30:78\u201383","journal-title":"Clin Dermatol"},{"key":"4385_CR71","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","volume":"16","author":"D Meyersburg","year":"2012","unstructured":"Meyersburg D, Schmidt E, Kasperkiewicz M et\u00a0al (2012) Immunoadsorption in dermatology. Ther Apher Dial 16:311\u2013320","journal-title":"Ther Apher Dial"},{"key":"4385_CR72","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","volume":"58","author":"DF Murrell","year":"2008","unstructured":"Murrell DF, Dick S, Ahmed AR et\u00a0al (2008) Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J\u00a0Am Acad Dermatol 58:1043\u20131046","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.021","author":"DF Murrell","year":"2018","unstructured":"Murrell DF, Pena S, Joly P et\u00a0al (2018) Diagnosis and management of pemphigus: recommendations by an international panel of experts. J\u00a0Am Acad Dermatol \n                  https:\/\/doi.org\/10.1016\/j.jaad.2018.02.021","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR74","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1038\/jid.2009.27","volume":"129","author":"A Nagel","year":"2009","unstructured":"Nagel A, Podstawa E, Eickmann M et al (2009) Rituximab mediates a\u00a0strong elevation of B\u2011cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J\u00a0Invest Dermatol 129:2202\u20132210","journal-title":"J Invest Dermatol"},{"key":"4385_CR75","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archderm.135.7.853","volume":"135","author":"HC Nousari","year":"1999","unstructured":"Nousari HC, Anhalt GJ (1999) The role of mycophenolate mofetil in the management of pemphigus. Arch Dermatol 135:853\u2013854","journal-title":"Arch Dermatol"},{"key":"4385_CR76","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jaad.2008.08.049","volume":"60","author":"AK Orvis","year":"2009","unstructured":"Orvis AK, Wesson SK, Breza TS Jr. et\u00a0al (2009) Mycophenolate mofetil in dermatology. J\u00a0Am Acad Dermatol 60:183\u2013199 (quiz 200\u2013182)","journal-title":"J Am Acad Dermatol"},{"key":"4385_CR77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/0378-6323.104672","volume":"79","author":"NV Parmar","year":"2013","unstructured":"Parmar NV, Kanwar AJ, Minz RW et\u00a0al (2013) Assessment of the therapeutic benefit of dexamethasone cyclophosphamide pulse versus only oral cyclophosphamide in phase II of the dexamethasone cyclophosphamide pulse therapy: a\u00a0preliminary prospective randomized controlled study. Indian J Dermatol Venereol Leprol 79:70\u201376","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"4385_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","volume":"54","author":"R Pollmann","year":"2018","unstructured":"Pollmann R, Schmidt T, Eming R et\u00a0al (2018) Pemphigus: a\u00a0comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clin Rev Allergy Immunol 54:1\u201325","journal-title":"Clin Rev Allergy Immunol"},{"key":"4385_CR79","unstructured":"Roche H\u2011L (2015) A randomized, double-blind, double-dummy, active-Comparator, multicenter study to evaluate the efficacy and safety of Rituximab versus MMF in patients with pemphigus vulgaris. clinicaltrials.gov: NCT02383589"},{"key":"4385_CR80","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1159\/000320413","volume":"28","author":"WJ Sandborn","year":"2010","unstructured":"Sandborn WJ (2010) State-of-the-art: immunosuppression and biologic therapy. Dig Dis 28:536\u2013542","journal-title":"Dig Dis"},{"key":"4385_CR81","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","volume":"14","author":"E Schaeffeler","year":"2004","unstructured":"Schaeffeler E, Fischer C, Brockmeier D et al (2004) Comprehensive analysis of thiopurine S\u2011methyltransferase phenotype-genotype correlation in a\u00a0large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14:407\u2013417","journal-title":"Pharmacogenetics"},{"key":"4385_CR82","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/S0140-6736(17)30787-0","volume":"389","author":"E Schmidt","year":"2017","unstructured":"Schmidt E (2017) Rituximab as first-line treatment of pemphigus. Lancet 389:1956\u20131958","journal-title":"Lancet"},{"key":"4385_CR83","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","volume":"34","author":"E Schmidt","year":"2008","unstructured":"Schmidt E, Brocker EB, Goebeler M (2008) Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 34:56\u201364","journal-title":"Clin Rev Allergy Immunol"},{"key":"4385_CR84","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","volume":"19","author":"E Schmidt","year":"2010","unstructured":"Schmidt E, Dahnrich C, Rosemann A et\u00a0al (2010) Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 19:458\u2013463","journal-title":"Exp Dermatol"},{"key":"4385_CR85","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1586\/17469872.3.3.259","volume":"3","author":"E Schmidt","year":"2008","unstructured":"Schmidt E, Goebeler M (2008) CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Rev Dermatol 3:259\u2013278","journal-title":"Expert Rev Dermatol"},{"key":"4385_CR86","first-page":"713","volume":"13","author":"E Schmidt","year":"2015","unstructured":"Schmidt E, Goebeler M, Hertl M et\u00a0al (2015) S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid. J\u00a0Dtsch Dermatol Ges 13:713\u2013727","journal-title":"J Dtsch Dermatol Ges"},{"key":"4385_CR87","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","volume":"1173","author":"E Schmidt","year":"2009","unstructured":"Schmidt E, Goebeler M, Zillikens D (2009) Rituximab in severe pemphigus. Ann N Y Acad Sci 1173:683\u2013691","journal-title":"Ann N Y Acad Sci"},{"key":"4385_CR88","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.clim.2009.05.007","volume":"132","author":"E Schmidt","year":"2009","unstructured":"Schmidt E, Hennig K, Mengede C et\u00a0al (2009) Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol 132:334\u2013341","journal-title":"Clin Immunol"},{"key":"4385_CR89","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1365-2133.2005.06740.x","volume":"153","author":"E Schmidt","year":"2005","unstructured":"Schmidt E, Herzog S, Brocker EB et al (2005) Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 153:449\u2013451","journal-title":"Br J Dermatol"},{"key":"4385_CR90","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2230.2006.02151.x","volume":"31","author":"E Schmidt","year":"2006","unstructured":"Schmidt E, Hunzelmann N, Zillikens D et\u00a0al (2006) Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 31:503\u2013508","journal-title":"Clin Exp Dermatol"},{"key":"4385_CR91","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1046\/j.1365-2133.2003.05302.x","volume":"148","author":"E Schmidt","year":"2003","unstructured":"Schmidt E, Klinker E, Opitz A et\u00a0al (2003) Protein A immunoadsorption: a\u00a0novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148:1222\u20131229","journal-title":"Br J Dermatol"},{"key":"4385_CR92","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","volume":"156","author":"E Schmidt","year":"2007","unstructured":"Schmidt E, Seitz CS, Benoit S et\u00a0al (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156:352\u2013356","journal-title":"Br J Dermatol"},{"key":"4385_CR93","first-page":"399","volume":"108","author":"E Schmidt","year":"2011","unstructured":"Schmidt E, Zillikens D (2011) The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int 108:399\u2013405 (I\u2013III)","journal-title":"Dtsch Arztebl Int"},{"key":"4385_CR94","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00403-009-1024-9","volume":"302","author":"E Schmidt","year":"2010","unstructured":"Schmidt E, Zillikens D (2010) Immunoadsorption in dermatology. Arch Dermatol Res 302:241\u2013253","journal-title":"Arch Dermatol Res"},{"key":"4385_CR95","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.autrev.2010.08.007","volume":"10","author":"E Schmidt","year":"2010","unstructured":"Schmidt E, Zillikens D (2010) Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 10:84\u201389","journal-title":"Autoimmun Rev"},{"key":"4385_CR96","first-page":"S97","volume":"129","author":"I Shimanovich","year":"2009","unstructured":"Shimanovich I, Bohmke AK, Westermann L et\u00a0al (2009) Successful treatment of severe pemphigus with the combination of immunoadsorption and rituximab. J\u00a0Invest Dermatol 129:S97","journal-title":"J Invest Dermatol"},{"key":"4385_CR97","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2230.2006.02220.x","volume":"31","author":"I Shimanovich","year":"2006","unstructured":"Shimanovich I, Herzog S, Schmidt E et\u00a0al (2006) Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 31:768\u2013774","journal-title":"Clin Exp Dermatol"},{"key":"4385_CR98","first-page":"800","volume":"123","author":"V Spindler","year":"2013","unstructured":"Spindler V, Rotzer V, Dehner C et al (2013) Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. J\u00a0Clin Invest 123:800\u2013811","journal-title":"J Clin Invest"},{"key":"4385_CR99","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.4049\/jimmunol.1002675","volume":"185","author":"V Spindler","year":"2010","unstructured":"Spindler V, Vielmuth F, Schmidt E et al (2010) Protective endogenous cyclic adenosine 5\u2032-monophosphate signaling triggered by pemphigus autoantibodies. J\u00a0Immunol 185:6831\u20136838","journal-title":"J Immunol"},{"key":"4385_CR100","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","volume":"53","author":"S Tavakolpour","year":"2017","unstructured":"Tavakolpour S (2017) Current and future treatment options for pemphigus: Is it time to move towards more effective treatments? Int Immunopharmacol 53:133\u2013142","journal-title":"Int Immunopharmacol"},{"key":"4385_CR101","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H et al (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a\u00a0national registry (GRAID). Arthritis Res Ther 13:R75","journal-title":"Arthritis Res Ther"},{"key":"4385_CR102","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1468-3083.2002.00413.x","volume":"16","author":"GG Toth","year":"2002","unstructured":"Toth GG, Van De Meer JB, Jonkman MF (2002) Dexamethasone pulse therapy in pemphigus. J\u00a0Eur Acad Dermatol Venereol 16:607\u2013611","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4385_CR103","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjd.12474","volume":"169","author":"KD Tran","year":"2013","unstructured":"Tran KD, Wolverton JE, Soter NA (2013) Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol 169:916\u2013921","journal-title":"Br J Dermatol"},{"key":"4385_CR104","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.4049\/jimmunol.172.10.6468","volume":"172","author":"C Veldman","year":"2004","unstructured":"Veldman C, Hohne A, Dieckmann D et\u00a0al (2004) Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J\u00a0Immunol 172:6468\u20136475","journal-title":"J Immunol"},{"key":"4385_CR105","first-page":"210","volume":"12","author":"N Vyas","year":"2013","unstructured":"Vyas N, Patel NS, Cohen GF (2013) Mycophenolate mofetil as a\u00a0first-line steroid-sparing agent in the treatment of pemphigus vulgaris. J Drugs Dermatol 12:210\u2013216","journal-title":"J. Drugs. Dermatol."},{"key":"4385_CR106","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","volume":"95","author":"HH Wang","year":"2015","unstructured":"Wang HH, Liu CW, Li YC et al (2015) Efficacy of rituximab for pemphigus: a\u00a0systematic review and meta-analysis of different regimens. Acta Derm Venereol 95:928\u2013932","journal-title":"Acta Derm Venereol"},{"key":"4385_CR107","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","volume":"21","author":"WK Weng","year":"2003","unstructured":"Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J\u00a0Clin Oncol 21:3940\u20133947","journal-title":"J Clin Oncol"},{"key":"4385_CR108","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1001\/archderm.1996.03890360021005","volume":"132","author":"VP Werth","year":"1996","unstructured":"Werth VP (1996) Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 132:1435\u20131439","journal-title":"Arch Dermatol"},{"key":"4385_CR109","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archderm.144.1.25","volume":"144","author":"VP Werth","year":"2008","unstructured":"Werth VP, Fivenson D, Pandya AG et al (2008) Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a\u00a0glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol 144:25\u201332","journal-title":"Arch Dermatol"},{"key":"4385_CR110","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/ki.1987.131","volume":"31","author":"JA Whitworth","year":"1987","unstructured":"Whitworth JA (1987) Mechanisms of glucocorticoid-induced hypertension. Kidney Int 31:1213\u20131224","journal-title":"Kidney Int"},{"key":"4385_CR111","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ng.3060","volume":"46","author":"SK Yang","year":"2014","unstructured":"Yang SK, Hong M, Baek J et al (2014) A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 46:1017\u20131020","journal-title":"Nat Genet"},{"key":"4385_CR112","first-page":"598","volume":"8","author":"J Zimmermann","year":"2010","unstructured":"Zimmermann J, Bahmer F, Rose C et\u00a0al (2010) Clinical and immunopathological spectrum of paraneoplastic pemphigus. J\u00a0Dtsch Dermatol Ges 8:598\u2013605","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4385-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-019-4385-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4385-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T09:15:45Z","timestamp":1585905345000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-019-4385-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":112,"alternative-id":["4385"],"URL":"https:\/\/doi.org\/10.1007\/s00105-019-4385-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"18 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0van Beek, D.\u00a0Zillikens und E.\u00a0Schmidt geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}